AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$CRBP

Saxena Nishant C purchased $101K of CRBP

Saxena Nishant C (Chief Business Officer) purchased 13,500 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at an average of $7.50 ($7.33–$7.58, $0.10M total) across 2 trades over 2026-06-02 to 2026-06-03.

Original reporting
SEC EDGAR · Saxena Nishant C
Published Jun 3, 2026, 9:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRBP
Bullish
medium confidence
Mentioned
$CRBP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRBPBullishLow
01

Why it matters

The filing provides a fresh data point on insider sentiment but the monetary size is modest.

02

Market read

A small insider purchase; limited trading relevance but may be noted by micro‑cap traders.

03

What to watch

Potential upcoming clinical data could be the real driver behind the insider's confidence.

Relevance 5/10Novelty 3/10Timing: after market today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$CRBPBullishMedium confidence
Context

Chief Business Officer bought 13,500 shares for $101,218, raising his stake to 75,300 shares.

Expected impact

modest upward pressure as the market prices in insider confidence

Evidence & confidence

A $101k purchase by a senior officer is a small but positive signal for a micro‑cap biotech.

Market effects

Sector

Limited impact on the broader biotech sector; typical insider trades are routine.

Regional

No significant regional effect; confined to CRBP shareholders.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    Corbus Pharmaceuticals Holdings, Inc.

    Biotech firm listed on Nasdaq under CRBP.

  • Person
    Saxena Nishant C

    Chief Business Officer of Corbus Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRBP insider trading history →

Related articles

SEP 15
$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

finance.biggo.com2 min
SEP 15
$CRBPMedAI 8/10

Obesity drug could have fewer side effects than GLP-1s

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development

foodnavigator.com2 min
SEP 14
$CRBPHighAI 8/10

Why is Corbus Pharmaceuticals stock surging today?

Corbus Pharmaceuticals (CRBP) stock rose 14.4% pre-market after reporting positive Phase 1b trial results for its obesity drug CRB-913, showing significant weight loss and a favorable safety profile. The company plans to present full data in November and initiate a Phase 2 study in 2027. The stock had been near its 52-week low before the announcement.

investing.com2 min
SEP 14
$CRBPHighAI 9/10

Corbus Pharmaceuticals stock rises on obesity drug trial data

Corbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.

investing.com2 min
SEP 14
$CRBPMedAI 9/10

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau obs

SEC EDGAR 8-K2 min